PTCT vs SRRK
PTCT: A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases. SRRK: Scholar Rock is a clinical-stage biopharma company pioneering anti-myostatin therapies to treat rare neuromuscular diseases like SMA by selectively inhibiting growth factor activation.
Side-by-side fundamentals
| Metric | PTCT | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $62.62 | $43.00 | |
| Market cap | $5.2B | $5.2B | |
| Net margin FY2025, SEC XBRL | +39.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +50.1% | n/a | |
| ROE FY2025, SEC XBRL | n/a | -154.0% | |
| ROA FY2025, SEC XBRL | +23.5% | -93.5% | PTCT higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.77 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +114.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +35.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.91 | 1.31 | |
| 1-year return as of 2026-10-21 close | -6.8% | +52.6% | SRRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.